nach oben

Reactions Weekly

Erschienen in:

01.11.2011 | Case report

Fluorouracil/gemcitabine

Nausea, vomiting and alopecia: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Excerpt

A 45-year-old man with metastatic prostate cancer began receiving IV gemcitabine 1000 mg/m² as a 0.5-hour infusion and IV fluorouracil 2000 mg/m² as a 24-hour infusion on days 1, 8 and 15, followed by one week of rest. He subsequently developed grade 1 nausea, vomiting and alopecia [duration of treatment to reactions onset not stated]. After 6 cycles of chemotherapy, he achieved partial remission and underwent complete resection of his primary tumour. He remained symptom- and relapse-free after 8 years of follow-up. …

Roehrig S, Wein A, Albrecht H, Maennlein G, Wolff K, Muskoski D, Amann K, Janka R, Hohenberger W, Hahn EG, Siebler J, Neurath MF, Boxberger F.Long-term relapse-free survival by interdisciplinary collaboration in a patient with metastatic pancreatic cancer (UICC IV). Case Reports in Oncology 4: 413-419, No. 2, Aug 2011. Available from: URL: http://dx.doi.org/10.1159/000331239 - Germany

Titel: Fluorouracil/gemcitabine
Nausea, vomiting and alopecia: case report
Publikationsdatum: 01.11.2011
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2011
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.2165/00128415-201113760-00050

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Fluorouracil/gemcitabine

Nausea, vomiting and alopecia: case report

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Etidronic acid

Lamotrigine

Pravachol [pravastatin] and Mevacor [lovastatin] have the best muscle-related safety profile of statins marketed in the US,

NSAIDs

Alendronic acid

Tacrolimus